Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
FAAH Inhibitor
CAY10435 is a β-ketooxazapyridine that selectively inhibits fatty acid amide hydrolase (FAAH). Demonstrating antimicrobial activity, CAY10435 binds non-competitively to FAAH in Dictyostelium discoideum with a dissociation constant (Kd) of 0.57 nM. This compound is valuable for studying FAAH-related pathways and exploring potential therapeutic applications targeting lipid signaling. -
FAAH Inhibitor
JNJ-42165279 dihydrochloride is a selective inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 70 nM for human FAAH and 313 nM for rat FAAH. This compound enhances endocannabinoid levels by preventing the breakdown of fatty acid amides, which can lead to increased pain relief and anti-inflammatory effects. JNJ-42165279 is utilized in research applications focusing on pain management, neuroprotection, and the modulation of the endocannabinoid system. -
FAAH Inhibitor
AZ513 is a reversible inhibitor of fatty acid amide hydrolase (FAAH), exhibiting IC50 values of 551 nM for human FAAH and 27 nM for rat FAAH. This compound effectively inhibits the hydrolysis of anandamide in human FAAH-transfected HEK293 cells, demonstrating an IC50 of 360 nM. AZ513 is suitable for research applications focusing on the modulation of endocannabinoid signaling pathways and the study of pain relief and neuroprotection mechanisms. -
FAAH Inhibitor
PHOP is a selective inhibitor of fatty acid amide hydrolase (FAAH), utilized in fluorometric assays to evaluate inhibitory activity. It effectively quantifies FAAH activity by detecting the release of 4-pyridin-1-ylbutyric acid in rat brain microsomes. PHOP's capability for direct measurement of FAAH activity through reversed-phase HPLC and fluorescence detection supports its potential as a foundational tool in the development of novel FAAH inhibitors. This reagent is instrumental in fatty acid signaling research and related therapeutic investigations. -
Thrombin/ Factor Xa Inhibitor
Ciraparantag is a potent inhibitor of thrombin and factor Xa, serving as a broad-spectrum reversal agent for various anticoagulants. This compound effectively neutralizes the effects of low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants, while sparing vitamin K antagonists and argatroban. Its unique mechanism makes Ciraparantag a valuable tool for research focused on anticoagulation reversal and hemostasis. -
Factor Xa Inhibitor
Dechloro Rivaroxaban is a potent, selective inhibitor targeting Factor Xa, demonstrating a Ki of 0.4 nM against human free FXa. This compound effectively inhibits prothrombinase activity and fibrin-associated FXa activity, exhibiting IC50 values of 2.1 nM and 92 nM, respectively. Dechloro Rivaroxaban is suitable for research applications focused on coagulation and antithrombotic drug development. -
Thrombin/Factor Xa Inhibitor
Ciraparantag acetate is a potent inhibitor of thrombin and factor Xa, serving as a broad-spectrum reversal agent for various anticoagulants, including low molecular weight heparins, unfractionated heparins, and certain direct oral anticoagulants, excluding vitamin K antagonists (VKAs). Its primary mechanism targets the coagulation pathway, facilitating the restoration of normal hemostasis in clinical situations where anticoagulation reversal is necessary. Ciraparantag acetate is valuable in research applications focused on anticoagulation management and hemostatic balance in cardiovascular studies. -
Factor Xa Inhibitor
Edoxaban impurity 6 is a chemical impurity associated with Edoxaban, a selective and potent oral inhibitor of factor Xa (FXa). It exhibits binding affinities with Kis of 0.561 nM for free FXa and 2.98 nM for prothrombinase, highlighting its significant role in anticoagulation. Research applications include studying the pharmacokinetics and safety profiles of FXa inhibitors, particularly in the context of stroke prevention and thromboembolic disorders. -
Factor Xa Inhibitor
Fidexaban is a potent Factor Xa inhibitor that plays a significant role in the modulation of the coagulation cascade. It is primarily utilized in cardiovascular disease research, providing valuable insights into thrombotic disorders and potential therapeutic strategies. Its mechanism of action contributes to the understanding of anticoagulant therapies and their implications in various pathological conditions. -
Factor Xa Inhibitor
FXIa-IN-7 is a selective, orally bioavailable inhibitor of Factor XIa, exhibiting an impressive IC50 value of 0.4 nM. This compound demonstrates potent antithrombotic potential, making it a valuable tool for research in coagulation pathways and thrombotic disorders. Its specificity towards Factor XIa positions FXIa-IN-7 as an important reagent for studies aimed at understanding the role of the intrinsic pathway in hemostasis and thrombosis. -
Factor Xa Inhibitor
Betrixaban hydrochloride is a highly potent and selective inhibitor of factor Xa (fXa), exhibiting an IC50 of 1.5 nM. This compound demonstrates significant antithrombotic activity, making it valuable for research applications focused on thrombosis and coagulation disorders. Betrixaban hydrochloride is suitable for studies investigating novel anticoagulant therapies and the mechanistic pathways of blood clotting. -
Factor Xa Inhibitor
Razaxaban hydrochloride is a selective and potent inhibitor of factor Xa, exhibiting a Ki of 0.19 nM. With over 5000-fold selectivity for factor Xa compared to other serine proteases, this compound effectively impedes the coagulation cascade. Additionally, Razaxaban hydrochloride displays thrombin inhibition with a Ki value of 540 nM, underscoring its significant antithrombotic properties. It is a valuable tool for research into anticoagulation therapies and the modulation of thrombotic disorders. -
Factor Xa Inhibitor
EMD 495235 is a potent and orally active inhibitor of coagulation factor Xa, exhibiting an IC50 of 5.5 nM and a Ki of 6.8 nM. This compound demonstrates significant anticoagulant activity, making it a valuable tool for research applications focused on thrombosis and hemostasis. EMD 495235 can be utilized to investigate the mechanisms of coagulation and evaluate potential therapeutic strategies for related disorders. -
Factor Xa Inhibitor
FXIa-IN-6 is a highly selective inhibitor of Factor XIa, demonstrating a Ki value of 0.3 nM. This compound is integral in studying the coagulation cascade and serves as a valuable tool in thrombosis research. Its ability to specifically target Factor XIa provides insights into potential therapies for clotting disorders while minimizing cross-reactivity with other serine proteases. -
Factor Xa Inhibitor
FXIa-IN-13 is a selective inhibitor of Factor Xa, displaying significant antithrombotic activity. This compound effectively inhibits arteriovenous thrombosis in both in vivo and in vitro models, making it a valuable tool for research on thrombosis and coagulation disorders. Its application in studying the mechanisms of blood clotting can provide insights into therapeutic strategies for cardiovascular diseases. -
Factor Xa Inhibitor
EMD-503982 is an orally bioavailable inhibitor of Factor Xa, a key enzyme in the coagulation cascade. By selectively inhibiting Factor Xa, this compound effectively reduces thrombin generation, making it a valuable tool in research focused on thrombosis and coagulation disorders. Its utility in various biological assays and preclinical studies further supports investigations into anticoagulant therapies and related cardiovascular research. -
Coagulation Factor Xa Inhibitor
L-Guluronic acid is a coagulation Factor Xa inhibitor that retains the inhibitory activity against Factor Xa while serving as a substitute for L-Iduronic acid in anticoagulant pentasaccharides derived from heparin-like substances. Its capacity to modulate coagulation processes makes it valuable in research focused on coagulation disorders, including deep vein thrombosis and pulmonary embolism. This compound facilitates the exploration of therapeutic strategies aimed at managing these significant vascular conditions. -
Factor Xa Inhibitor
RPR 130737 is a selective and potent competitive inhibitor of Factor Xa, exhibiting an inhibition constant (Ki) of 2.4 nM. This compound demonstrates over 1000-fold selectivity against thrombin, activated protein C, plasmin, tissue-plasminogen activator, and trypsin, making it an ideal tool for cardiovascular research. RPR 130737 effectively prolongs both activated partial thromboplastin time and prothrombin time while having no impact on platelet aggregation. It is primarily utilized in studies relating to thrombotic disorders and cardiovascular diseases. -
Factor Xa Inhibitor
RPR-208707 is a selective inhibitor of Factor Xa, exhibiting a Ki of 18 nM. This compound demonstrates significant anti-thrombotic activity, making it a valuable tool for research focused on thrombosis-related diseases. Its specificity for Factor Xa positions it as a potent candidate for exploring mechanisms of coagulation and potential therapeutic interventions in thrombotic disorders. -
Thrombin/Factor Xa Inhibitor
Ciraparantag TFA is a potent thrombin and factor Xa inhibitor utilized as a broad-spectrum reversal agent for anticoagulants. It effectively antagonizes the effects of various anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and specific direct oral anticoagulants, while sparing vitamin K antagonists and argatroban. This compound is significant for research applications focused on enhancing hemostatic management in patients receiving anticoagulant therapy. -
Thrombin/Factor Xa/Trypsin/Papain Inhibitor
Bacithrocin D is a potent inhibitor of key proteases, specifically targeting thrombin, factor Xa, trypsin, and papain. It effectively prolongs clotting time, making it valuable in studies related to coagulation and hemostasis. Bacithrocin D demonstrates IC50 values of 124 μM for thrombin, 9 μM for factor Xa, 0.85 μM for trypsin, and a remarkable 0.01 μM for papain, showcasing its high potency against these proteases. This reagent is useful for investigating protease-related pathways and developing therapeutic strategies in anticoagulation research. -
Factor Xa Inhibitor
(1R,2R,4R)-Edoxaban is a selective inhibitor of activated coagulation factor X (Factor Xa). It demonstrates potent anticoagulant activity, making it a valuable tool in the study of thrombosis and related cardiovascular conditions. This reagent is suitable for researching mechanisms of coagulation and evaluating therapies aimed at managing thromboembolic disorders. -
Factor Xa Inhibitor
BI-11634 is a potent factor Xa inhibitor that plays a critical role in anticoagulant research. It is primarily metabolized by the enzyme CYP3A4, leading to the formation of a major metabolite. The metabolism of BI-11634 can be inhibited by Quinidine, demonstrating a Ki value of 7 µM, indicating its potential importance in studies related to drug interactions and cardiovascular therapeutics. -
Factor Xa Inhibitor
Darexaban glucuronide is an active metabolite of darexaban, functioning as a potent inhibitor of Factor Xa. This compound exhibits significant oral bioactivity and demonstrates antithrombotic effects, making it valuable for research into thromboembolic disorders. Its properties support studies focused on anticoagulant therapies and the mechanistic understanding of coagulation pathways. -
Factor Xa Inhibitor
AS1468240 is a potent, orally active inhibitor of factor Xa (fXa), demonstrating an IC50 of 8.7 nM against human fXa. This compound effectively prolongs coagulation time in murine models, highlighting its potential as an anticoagulant agent. It serves as a valuable tool for research into coagulation pathways and the development of therapeutic strategies for thromboembolic disorders. -
Factor Xa Inhibitor
Tanogitran is a dual inhibitor that targets Factor Xa and thrombin, exhibiting Ki values of 26 nM and 2.7 nM, respectively. This compound demonstrates significant anticoagulant activity, making it valuable for research in thrombotic diseases and related cardiovascular studies. Researchers can utilize Tanogitran to investigate the mechanisms of coagulation and the potential therapeutic applications in anticoagulation therapy. -
HMG-CoA Inhibitor
L-669,262 is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, exhibiting an IC50 of 0.10 ng/mL in rat liver preparations. This compound effectively downregulates cholesterol synthesis, making it a valuable tool in lipid metabolism research and studies focused on cardiovascular disease. Its specificity and high potency facilitate a wide range of applications in pharmacological studies and drug development targeting dyslipidemia. -
HMG-CoA Reductase Inhibitor
Pitavastatin magnesium is a potent HMG-CoA reductase inhibitor that plays a critical role in lipid metabolism. It effectively reduces total cholesterol and low-density lipoprotein cholesterol levels, as demonstrated in hyperlipidemic rat models. This compound is valuable for research focused on cardiovascular and cerebrovascular diseases, particularly in studies investigating hyperlipidemia and its associated conditions. -
HMG-CoA Reductase (HMGCR) Inhibitor
L 668411 is a β-lactone compound that acts as an inhibitor of HMG-CoA Reductase (HMGCR), targeting cholesterol biosynthesis. It effectively inhibits rat liver cytosolic 3-hydroxy-3-methylglutaryl-CoA synthase and reduces [14C] acetate incorporation into sterols in Hep G2 cell cultures. The inhibition demonstrates an irreversible mechanism in cellular systems, while exhibiting reversible properties in cultured cells and animal models, making it a valuable tool for studying cholesterol metabolism and related diseases. -
HMG-CoA Reductase Inhibitor
Tenivastatin calcium is an HMG-CoA reductase inhibitor that effectively lowers cholesterol levels by inhibiting the rate-limiting step in cholesterol biosynthesis. This compound has potential applications in the study of hyperlipidemia and cardiovascular disease, providing insights into lipid metabolism and associated disorders. Researchers can utilize Tenivastatin calcium to explore therapeutic strategies aimed at managing lipid abnormalities. -
HMG-CoA Reductase Inhibitor
Glenvastatin is a potent inhibitor of HMG-CoA reductase, an enzyme critical in the cholesterol biosynthesis pathway. This compound effectively reduces plasma levels of total cholesterol and phospholipids, as well as liver cholesterol content, without increasing cholesterol or total bile acids in gallbladder bile. Glenvastatin is valuable for research focused on hyperlipidemia and related metabolic disorders. -
HMG-CoA Reductase Inhibitor
(3S,5R)-Fluvastatin-d6 sodium is a deuterium-labeled derivative of the HMG-CoA reductase inhibitor, (3S,5R)-Fluvastatin. This compound exhibits a potent inhibitory activity with an IC50 of 8 nM, making it valuable for studying cholesterol biosynthesis. In addition to its role in lipid regulation, Fluvastatin has been shown to protect vascular smooth muscle cells from oxidative stress via the Nrf2-dependent antioxidant pathway, offering insights for cardiovascular research applications. -
HMG-CoA Reductase Inhibitor
Dalvastatin is a potent inhibitor of HMG-CoA reductase, a key enzyme involved in cholesterol biosynthesis. By effectively reducing cholesterol levels, Dalvastatin demonstrates significant potential in the management of hyperlipidemia and related cardiovascular conditions. Its ability to modulate lipid profiles makes it a valuable tool for research into lipid metabolism and cardiovascular disease therapeutics. -
HMG-CoA Reductase Inhibitor
GR 92549 is a potent, orally active inhibitor of HMG-CoA reductase, targeting the enzyme responsible for cholesterol biosynthesis. This compound effectively reduces cholesterol levels and may serve as a significant tool in metabolic and cardiovascular research. Its capability to modulate cholesterol metabolism makes it valuable for studies related to dyslipidemia and atherosclerosis. -
HMG-CoA Reductase (HMGCR) Inhibitor
Rawsonol is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a key enzyme in the cholesterol biosynthesis pathway. Derived from the green alga Avrainuika rawsoni, Rawsonol demonstrates significant inhibitory activity, making it a valuable tool for research investigating cholesterol regulation and related metabolic pathways. Its role as an HMGCR inhibitor positions it for applications in studies of lipid metabolism and cardiovascular health. -
HMG-CoA Reductase Inhibitor
(3S,5R)-Pitavastatin calcium functions primarily as an inhibitor of HMG-CoA reductase, a key enzyme in cholesterol biosynthesis. This enantiomer exhibits significant lipid-lowering activity, making it valuable for research into dyslipidemia and cardiovascular disease. Its efficacy in modulating lipid profiles has led to its application in studies focused on metabolic disorders and therapeutic approaches for hypercholesterolemia. -
Herbicide Agent/4-HPPD Inhibitor
Benzobicyclon is an effective 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) inhibitor exhibiting herbicidal properties. It hydrolyzes in the presence of water to produce the active agent benzobicycline, leading to the bleaching and subsequent death of various weed species. This reagent demonstrates efficacy against grass, sedge, and broadleaf weeds, including biotypes that are resistant to sulfonylurea herbicides, making it a valuable tool for herbicide resistance research and weed management studies. -
HPPD/PPO Dual Inhibitor
HPPD/PPO-IN-1 is a dual inhibitor targeting 4-hydroxyphenylpyruvate dioxygenase (HPPD) and protoporphyrinogen oxidase (PPO), exhibiting IC50 values of 0.12 μM and 0.51 μM, respectively, for Arabidopsis thaliana HPPD and Nicotiana tabacum PPO. This compound demonstrates broad-spectrum herbicidal activity against various weed species while maintaining safety for crops such as peanuts and cotton. HPPD/PPO-IN-1 is suitable for research focused on the development of environmentally sustainable herbicides. -
IDO1 Inhibitor
Amg-1 is a potent and reversible inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with an IC50 value of 3.0 μM. It demonstrates significant selectivity, with over 80-fold greater inhibition of IDO1 compared to IDO2 and over 20-fold selectivity against TDO. This compound is valuable for research in cancer, hypotension, and neurological disorders, facilitating the exploration of therapeutic strategies targeting immune regulation and metabolism. -
Apo-IDO1 Inhibitor
IDO1-IN-28 is an Apo-IDO1 inhibitor that disrupts heme binding with an IC50 of 1.29 μM. This compound selectively targets apo-IDO1, offering a valuable tool for studying its role in tumor immunology. IDO1-IN-28 is applicable in cancer research, facilitating investigations into the modulation of immune responses in various malignancies. -
IDO Inhibitor
(S)-Indoximod is a selective inhibitor of indoleamine 2,3-dioxygenase (IDO), with a Ki value of 19 μM. This compound has demonstrated notable biological activity in modulating immune responses and has potential applications in cancer research and the study of neurological disorders. Its ability to inhibit IDO activity makes it a valuable tool for investigating therapeutic strategies in various disease contexts. -
IDO1/TDO Inhibitor
IDO1/TDO-IN-4 is a dual inhibitor targeting indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO), exhibiting IC50 values of 3.53 μM and 1.15 μM, respectively. It interacts with IDO1 through hydrogen bonding and engages TDO via π−π stacking interactions. This compound is valuable for investigating the role of IDO1/TDO in depression and related conditions, including infectious, metabolic, and autoimmune disorders. -
IDO1 Inhibitor
DP00477 is a potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), exhibiting an IC50 value of 7.0 µM. This compound is valuable for investigating the role of IDO1 in tumor immune evasion and has potential applications in cancer research. Its inhibitory effects can facilitate studies on the modulation of the immune response in cancer therapy. -
IDO1 Inhibitor
IDO1-IN-18 is a potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), a critical enzyme in tryptophan metabolism that plays a role in immune regulation and tumor immune evasion. This compound demonstrates significant biological activity in inhibiting IDO1, which may enhance anti-tumor immune responses. IDO1-IN-18 is valuable for research applications in cancer biology and immunology, particularly in studies exploring the modulation of immune responses in tumor microenvironments. -
IDO1/IDO2 Inhibitor
IDO1/2-IN-1 is a novel dual inhibitor targeting indoleamine 2,3-dioxygenase 1 (IDO1) and IDO2, with IC50 values of 28 nM and 144 nM, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. The orally active nature of IDO1/2-IN-1 enhances its potential for in vivo studies, facilitating the exploration of immunomodulatory effects and therapeutic applications in oncology. -
IDO1/TDO Inhibitor
IDO1/TDO-IN-9 is a potent dual inhibitor targeting indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO), exhibiting IC50 values of less than 1 μM. This compound effectively inhibits the enzymatic activity of IDO1 and TDO, thereby blocking the degradation of tryptophan to kynurenine. By restoring immune activity within the tumor microenvironment, IDO1/TDO-IN-9 shows potential in suppressing tumor growth, making it a valuable tool for cancer research. -
IDO1 Inhibitor
4-Phenyl-1H-1,2,3-triazole is a potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with an IC50 value of 60 μM. This compound plays a crucial role in cancer research by modulating immune responses and inhibiting tumor-induced immune tolerance. Its ability to interfere with the kynurenine pathway makes it a valuable tool for studying tumor microenvironments and exploring new therapeutic strategies in oncology. -
IDO1 Inhibitor
BMS-986242 is a selective, orally active inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1). This compound demonstrates potent inhibition of IDO1 enzymatic activity, a critical pathway in the immunosuppressive tumor microenvironment. Research applications include exploring its use in combination therapies for cancer treatment and investigating its effects on immune response modulation. -
IDO Inhibitor
IDO2-IN-1 is a potent inhibitor of Indoleamine 2,3-dioxygenase 2 (IDO2), exhibiting an IC50 value of 112 nM. This compound is designed for use in research related to inflammatory autoimmunity, providing valuable insights into the mechanisms of immune modulation. Its ability to selectively inhibit IDO2 activity positions it as a crucial tool for exploring therapeutic strategies in related disease contexts. -
IDO Inhibitor
Kushenol E is a flavonoid derived from Sophora flavescens and acts as a non-competitive inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with an IC50 of 7.7 µM and a Ki of 9.5 µM. This compound exhibits notable anti-tumor activity, making it relevant for research applications in cancer biology and immunotherapy. Its mechanism of action provides potential insights into immune modulation within the tumor microenvironment.
